How Gilead Sciences, Inc. could strengthen its liver disease franchise through Hepcludex commercialization
FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.
Pharma & Biotech